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ABSTRACT
Objective Impulse control disorders are commonly
associated with dopaminergic therapy in Parkinson’s
disease (PD). PD patients with impulse control disorders
demonstrate enhanced dopamine release to conditioned
cues and a gambling task on [11C]raclopride positron
emission tomography (PET) imaging and enhanced
ventral striatal activity to reward on functional MRI. We
compared PD patients with impulse control disorders
and age-matched and gender-matched controls without
impulse control disorders using [123I]FP-CIT (2β-
carbomethoxy-3β-(4-iodophenyl)tropane) single photon
emission computed tomography (SPECT), to assess
striatal dopamine transporter (DAT) density.
Methods The [123I]FP-CIT binding data in the striatum
were compared between 15 PD patients with and 15
without impulse control disorders using independent
t tests.
Results Those with impulse control disorders showed
signiﬁcantly lower DAT binding in the right striatum with
a trend in the left (right: F(1,24)=5.93, p=0.02; left:
F(1,24)=3.75, p=0.07) compared to controls.
Conclusions Our ﬁndings suggest that greater
dopaminergic striatal activity in PD patients with impulse
control disorders may be partly related to decreased
uptake and clearance of dopamine from the synaptic
cleft. Whether these ﬁndings are related to state or trait
effects is not known. These ﬁndings dovetail with reports
of lower DAT levels secondary to the effects of
methamphetamine and alcohol. Although any regulation
of DAT by antiparkinsonian medication appears to be
modest, PD patients with impulse control disorders may
be differentially sensitive to regulatory mechanisms of
DAT expression by dopaminergic medications.
INTRODUCTION
Impulse control disorders (ICDs) are commonly
associated with dopaminergic therapy and can occur
in over 17% of those on dopamine agonists for
Parkinson’s disease (PD).1 The behaviours, includ-
ing pathological gambling, hypersexuality, binge
eating, compulsive shopping and punding, can have
signiﬁcant ﬁnancial and social consequences.
Why this subset of patients with PD develops these
behaviours has been the focus of recent research.
Several lines of evidence point towards enhanced stri-
atal dopaminergic activity in PD patients with ICDs
as compared to those without ICDs. PD patients with
pathological gambling as compared to PD controls
show greater ventral striatal dopamine release to a
gambling task measured using [11C]raclopride posi-
tron emission tomography (PET).2 [11C]raclopride is
a ligand-binding D2 and D3 receptors and can
provide an index of presynaptic dopamine release or
D2/D3 receptor density. In this same study, PD
patients with pathological gambling had lower [11C]
raclopride binding to a motor control task which the
authors interpret as suggesting decreased expression
of D2/D3 receptors. Similarly, in response to visual
cues, PD patients with mixed ICDs as compared to
PD controls have greater ventral striatal and posterior
putaminal dopamine release, consistent with a clas-
sical cue-conditioning response.3 In contrast to the
previous study, there were no differences at baseline
between the two groups. PD patients with mixed
ICDs also show greater blood oxygen level–depend-
ent ventral striatal activity in functional MRI (fMRI)
in a probabilistic learning task to unexpected and
expected reward.4 Similarly, PD patients with com-
pulsive medication use or punding symptoms also
have enhanced ventral striatal dopamine release to
levodopa as measured using [11C]raclopride PET.5
Whether this enhanced detection of striatal dopa-
mine is solely related to greater dopamine release or
whether dopamine might also be more likely to
remain in the synaptic cleft due to decreased uptake
and clearance via the dopamine transporter
(DAT) remains unclear. Using [123I]FP- CIT (2β- car-
bomethoxy-3β-(4-iodophenyl)tropane) single photon
emission computed tomography (SPECT), which
binds dopamine and serotonin transporters, a small
study with 8 PD patients with pathological gambling,
21 matched PD controls and 14 healthy controls
demonstrated lower transporter density in the ventral
striatum in PD+ICD patients.6 The authors suggest
that rather than a reduction in mesolimbic dopamin-
ergic projections, this decrease in DAT density is likely
related to a downregulation of striatal DAT, consistent
with the previous reports of greater striatal dopamine
release. Here, we study a much larger sample size of
PD patients with ICDs and compare with age-matched
(±5 years) and gender-matched PD controls using
[123I]FP-CIT SPECTand hypothesise a decrease in stri-
atal DAT density in PD patients with ICDs.
METHODS
PD subjects were recruited from Kings College
Hospital Movement Disorders clinic among
patients who underwent routine [123I]FP-CIT
SPECT as part of the clinical assessment of PD to
detect loss of functional dopaminergic neuron
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terminals. Fifteen subjects were identiﬁed with a diagnosis of
idiopathic PD and a current ICD at the time of scanning with
diagnoses that ﬁt established criteria for pathological gambling,
compulsive shopping, binge eating, compulsive hypersexuality
and punding (diagnostic criteria reviewed in ref. 7). Five subjects
had punding or hobbyism as their sole behaviour. No subject
had compulsive medication use or a history of ICDs prior to the
onset of dopaminergic medications. From the same clinic,
ﬁfteen age-matched and gender-matched subjects with idio-
pathic PD without a history of ICDs were identiﬁed as controls.
SPECT studies were carried out at the Nuclear Medicine
Department at Kings College Hospital in London, UK.
In compliance with the EANM 2010 Imaging Guidelines,
patients were required to stop any medication that would bind to
the DAT 7 days prior to the scan including amphetamine, benztro-
pine, bupropion, cocaine, mazindol, methylphenidate, phenter-
mine and sertraline. None of the subjects were on these
medications. Subjects were continued on their dopaminergic med-
ications. Oral potassium iodate was administered for thyroid
blockade 24 h prior to the study. Patients were scanned 4 h after a
slow intravenous injection of 185 MBq (5 mCi) [123I]FP-CIT
(Ioﬂupane, GE Healthcare, Arlington Heights, Illinois, USA). The
40-min SPECTacquisition was performed with the patient supine
on a Philips SKYLight dual-head gamma camera with a low-energy
general purpose collimator; the patient’s head in the ﬁeld of view
being lightly restrained as to enable the smallest possible rotational
radius. Patients were not sedated for the imaging sequence.
Imaging parameters used included a clockwise step and shoot
protocol of 40 s for each of the 120 azimuths, a 128×128×16
matrix, a 20% energy window centred at 159 keV with no zoom.
After ensuring the absence of patient’s motion and applying
motion correction as required, images were reconstructed on a
Adac Pegasus workstation using a ﬁltered backprojection algo-
rithm using a Butterworth low-pass ﬁlter (order=8, cut-off=0.7).
The software program BRAS on Hermes workstation was used to
automatically delineate circular regions of interest (ROIs) over the
caudate and putamina on the transaxial images and the overall
striata on the coronal images. A single ROI over the occipital lobe
provides the background (non-speciﬁc) uptake area. These ROIs
were checked and realigned manually if needed. Quantitation in
the form of speciﬁc ratios for each caudate/ putamen and the
overall striata were calculated as follows:
FP-CIT binding in area of uptake=[(mean counts per pixel in
the ROI in area of uptake)−(mean counts per pixel in the occipi-
tal cortex)]/(mean counts per pixel in the occipital cortex).
These ratios were not adjusted for age or gender. The images
were viewed on a workstation by an experienced nuclear phys-
ician blinded to the ICD status to assess the overall SPECT
binding pattern. Areas of reduced uptake within the striata were
reported with description of the intensity and location as well as
a comment on the quantitative value. All subjects received
informed consent, and the study was approved by the local
research ethics committee.
Statistics
The binding data were compared between PD+ICD and PD
−ICD groups. Parametric tests were used after the data were
tested for normal distribution using Shapiro–Wilk test. The
subject characteristics were compared using independent t tests.
The binding data in the right and left caudate and putamen
were then compared using multivariate analyses between
groups.
RESULTS
Fifteen PD+ICD subjects were compared with 15 age-matched
and gender-matched PD−ICD controls. There were no differ-
ences in gender, age, PD duration, H+Y score or dopaminergic
medication dose calculated as levodopa dose equivalence8
between the groups (table 1). In the PD+ICD group, 13/14
were on dopamine agonists (pramipexole=4, ropinirole=8,
rotigotine=2) at the time of their ICD symptoms with one
subject on amantadine. The PD+ICD DAT binding data of one
subject was not included as the scores were outliers (score >3
SD above group mean).
Compared to PD−ICD subjects, PD+ICD patients had lower
DAT binding in bilateral striatum (table 2 and ﬁgure 1).
Although there were no differences in age or PD duration
between groups, since age and PD duration are known to affect
DAT expression, the group differences were also compared with
univariate analysis using age and PD duration as covariates of
no interest. The difference in the right striatum remained signiﬁ-
cantly different in PD+ICD patients when covaried for age and
PD duration with a trend in the left striatum (right: F(1,24)
=5.93, p=0.02; left: F(1,24)=3.75, p=0.07). The different
Table 1 Subject and disease characteristics
PD−ICD PD+ICD df t p Value
N 15 15
Gender in No males (%) 9 (60) 9 (60)
Age in years old 60.13 (7.98) 55.07 (8.91) 28 1.61 0.12
PD duration in years 5.53 (5.21) 7.54 (5.39) 28 −0.99 0.33
Median H+Y score 3.00 3.00 28 0.19 0.86
Total LEDD in mg/d (n) 852.15 (520.37)
(14)
785.80 (402.73)
(13)
26 0.32 0.75
No of dopamine agonist 10 13
Dopamine agonist LEDD in mg/d 384.33 (212.85) 325.77 (156.10) 22 0.07 0.94
Behaviours CS: 5
HS: 4
PG: 3
Punding/hobbyism: 6
All values reported as mean (SD) unless otherwise indicated.
CS, compulsive shopping; HS, hypersexuality; ICD, impulse control disorders; LEDD, levodopa dose daily equivalent; mg/d, milligrams/day; n, number of subjects; PD, Parkinson’s
disease; PG, pathological gambling.
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striatal regions were also compared using a multivariate analysis
using age and PD duration as covariates of no interest: the right
caudate (F(1,24)=8.91, p=0.006), right putamen (F(1,24)
=6.60, p=0.02) and left putamen (F(1,24)=4.59, p=0.04)
remained signiﬁcant with a trend towards signiﬁcance in the left
caudate (F(1,24)=4.18, p=0.052).
The binding data of the different striatal regions of the behav-
iour were then compared between PD−ICD, PD+ICD (n=9)
and punding only (n=5) using multivariate analyses. There were
signiﬁcant differences in the right caudate (F(2,24)=3.65,
p=0.04) and right putamen (F(2,24)=3.64, p=0.04) but not in
the left caudate (F(2,24)=1.83, p=0.18) or the left putamen
(F(2,24)=2.48, p=0.10) (ﬁgure 1). PD+ICD had signiﬁcantly
lower DAT binding compared to PD−ICD in the right caudate
(mean difference 0.76 (SEM 0.28), p=0.01) and right putamen
(0.64 (SEM 0.24), p=0.01) on post hoc analyses with no other
signiﬁcant differences documented.
DISCUSSION
We show that PD+ICD patients have lower striatal DAT levels
relative to matched PD−ICDs controls with similar Hoehn and
Yahr stage severity. Dopamine reuptake via the sodium chloride-
dependent DAT, a membrane-spanning protein located in the
axon terminals, is the primary mechanism by which striatal
dopamine is removed from the synaptic cleft and dopamine
neurotransmission regulated and terminated. These ﬁndings may
help explain the observation of enhanced ventral striatal activity
and enhanced dopamine release in PD+ICD patients. In
response to conditioned cues or to a gambling task, PD+ICD
patients demonstrate increased ventral striatal dopamine release
as measured using [11C]raclopride. Similarly in response to
conditioned cues or to unexpected and anticipated rewards,
PD+ICD patients demonstrated increased ventral striatal activ-
ity.3 4 9 Our ﬁndings suggest that one possible explanation for
the enhanced dopaminergic activity is that impaired clearance of
dopamine may play a role in extending the physiological effect
of dopamine at the synaptic terminal. This ﬁnding extends pre-
vious observations of lower DAT ventral striatal expression in a
smaller sample size of PD and gambling patients.6
Our ﬁndings also suggest that DAT density may be decreased
in PD+ICD subjects but this observation may not hold for
those with punding behaviours. In the subanalysis, the differ-
ences between PD+ICD and PD−ICD remained signiﬁcant and
there were no differences in DAT binding between those with
punding/hobbyism and PD−ICD. Punding has been associated
with levodopa10 rather than dopamine agonists and underlying
mechanisms may differ from that of ICDs. Although our sample
size of subjects with punding/hobbyism (n=5) was too small to
draw any conclusions, our preliminary ﬁndings are indicative of
differences between ICDs and punding.
The binding levels of [123I]FP-CIT may reﬂect either lower
DAT levels or greater dopaminergic nerve terminal degener-
ation. There is no clear clinical evidence for a greater decrease
in dopaminergic terminals in PD+ICD patients relative to PD
controls. In a large multicenter study, motor severity as mea-
sured using UPDRS III or H+Y staging was not different
between PD+ICD and PD−ICD controls suggesting similar
putaminal dopaminergic nerve terminal density.1 11 However,
the association of PD+ICD with greater levodopa dose1 sug-
gests possibly the necessity for higher levodopa doses to main-
tain a similar level of motor functioning. As discussed, several
lines of evidence have shown greater ventral striatal dopamin-
ergic release to incentive cues and a gambling task and enhanced
ventral striatal activity to reward.2–4 PD patients with mixed
ICDs have also been shown to have a 35% increase in [18F]ﬂur-
odopa uptake in the medial orbitofrontal cortex with no differ-
ences in striatal uptake compared to PD controls. Together,
these ﬁndings suggest that rather than the lower binding levels
of [123I]FP-CIT reﬂecting greater dopaminergic nerve terminal
degeneration and hence lower dopaminergic activity, this sug-
gests that the lower binding levels might either reﬂect greater
sensitivity to medication-related DAT downregulation or base-
line trait differences and hence higher dopaminergic activity.
Lower DAT levels with similar nerve terminal density suggest
that extracellular dopamine neurotransmission can be enhanced
in distance from the synaptic cleft and duration of action.
Figure 1 [123I]FP-CIT single photon
emission computed tomography
(SPECT) binding values. PD,
Parkinson’s disease; ICD, impulse
control disorders; R, right; L, left.
Table 2 Binding values
PD−ICD PD+ICD Error F p Value
R striatum 1.43 (0.68) 0.91 (0.41) 27 6.22 0.02
L striatum 1.45 (0.67) 0.98 (0.47) 27 4.87 0.04
R caudate 1.68 (0.71) 1.06 (0.63) 27 6.12 0.02
L caudate 1.57 (0.60) 1.13 (0.62) 27 3.77 0.06
R putamen 1.14 (0.68) 0.63 (0.41) 27 5.80 0.02
L putamen 1.23 (0.75) 0.70 (0.48) 27 5.14 0.03
R caudate:putamen ratio 1.70 (0.55) 1.78 (0.57) 27 0.15 0.71
L caudate:putamen ratio 1.54 (0.56) 1.81 (0.61) 27 1.45 0.24
All values reported as mean (SD).
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There are several reasons why DAT binding may be
decreased. In PD+ICD subjects, there may be underlying differ-
ences in genetic expression of DAT or alternatively, an inter-
action between dopaminergic medications and DAT regulation.
For instance, differences in the variable number tandem repeat
at the 30 end of the gene for DAT, DAT1, can affect basal trans-
porter expression. However, in a small study, no differences in
DAT1 polymorphisms were noted between PD+ICD (n=41)
and PD controls.12
Alternatively, multiple substances of abuse, such as metham-
phetamine, cocaine and alcohol, can differentially affect the regu-
lation of DAT. For instance, methamphetamine is associated with
decreased DAT density as measured using PET imaging and DAT
ligands.13 14 This decrease in DAT density has been shown in
early abstinence (<6 months) with some degree of recovery after
prolonged abstinence (12–16 months).15 However, given that
cognitive deﬁcits persist following prolonged abstinence from
methamphetamine, the partial recovery was not suggested to be
functionally sufﬁcient.15 Similarly, alcohol-dependent subjects in
early abstinence during detoxiﬁcation and withdrawal have lower
DAT levels as measured using [123I]FP-CIT SPECT, which nor-
malises at 4 weeks of abstinence.16 In contrast, cocaine, which
acts directly to inhibit DAT, increases DAT in early abstinence as
measured using [99mTc]TRODAT and [123I]FP-CIT SPECT17–19
consistent with ﬁndings in postmortem studies. This observation
may also play a mechanistic role in the behavioural responses
observed in PD+ICD subjects. For instance, in cocaine depend-
ence, which acts through DAT inhibition with subsequent
increases in dopamine levels, the degree of DAT occupancy is
associated with the subjective experience of a ‘high’.20
In contrast to the effects of substances of abuse, the effects of
levodopa or dopamine agonists on DATregulation in PD are less
pronounced. Short-term 6-week administration of either levo-
dopa (−16% to −22%) or pramipexole (−15% to −20%) in
early PD has been shown to modestly downregulate DAT
compared to placebo (−12%) as measured using [11C]RTI-32
PET imaging.21 In contrast, short-term 6-week pergolide
co-administration with levodopa for dyskinesia in PD patients
was associated with a trend towards DAT upregulation (8%) as
measured using [123I]FP-CIT SPECT.22 The trend normalised fol-
lowing a 4-week pergolide washout. Short-term 6-week treat-
ment with levodopa did not demonstrate any differences in DAT
binding in early PD as measured using [123I]FP-CIT SPECT.23
Thus, DAT regulation by levodopa or dopamine agonists, if any,
appears to be modest and its effect might be dependent on its use
in early versus late PD or as monotherapy versus co-therapy.
Although any regulation of DAT by antiparkinsonian medications
appears to be modest, PD+ICD patients may be differentially
sensitive to regulatory mechanisms of DAT expression (eg, D2
autoreceptor, TAAR1, protein kinase A and C, reviewed in ref.
24) compared to PD controls. A mechanism implicating DAT
downregulation would also suggest that symptom improvement
following discontinuation of the dopamine agonist would have a
delayed timecourse. This may also play a role in the observation
of enhanced dopamine withdrawal symptoms observed following
dopamine agonist discontinuation in PD patients with ICDs.25
Although we focus here on DAT levels and the role of
impaired clearance from the synaptic cleft, other dopamine
regulatory mechanisms may also be implicated in the observa-
tion of enhanced dopaminergic activity in PD+ICD patients.26
Although acute dopamine agonist (pramipexole) administration
in rodents has been shown to decrease the proportion of spon-
taneously ﬁring dopaminergic neurons, chronic dopamine ago-
nists normalise this proportion of ﬁring neurons mediated via
D2/D3 autoreceptor downregulation.27 Furthermore, chronic
levodopa administration in a Parkinsonian rodent model has
been shown to increase the proportion of spontaneously ﬁring
dopaminergic neurons, secondary to D2/D3 autoreceptor down-
regulation.28 These spontaneously ﬁring dopaminergic neurons
are the neurons that are capable of phasic activity in response to
a stimulus (eg, the unconditioned rewarding stimulus, condi-
tioned stimulus, a gambling task).29 Thus, increasing the propor-
tion of spontaneously ﬁring neurons effectively increases the
gain and proportion of dopamine neurons capable of phasically
responding to a stimulus. Preliminary evidence exists that PD
patients with ICDs have decreased sensitivity of the D2/D3
autoreceptor in the midbrain as measured using [11C]FLB-457
PET.30 In this study, PD controls on dopamine agonists demon-
strated decreased D2/D3 midbrain autoreceptor binding to a
gamble task as compared to a control task, consistent with the
feedback regulation of endogenous dopamine released in the
gamble task. In contrast, PD patients with ICDs on dopamine
agonists failed to demonstrate a difference suggesting decreased
sensitivity of the D2/D3 autoreceptor. Thus, the enhanced dopa-
mine levels observed in PD+ICD may be related to impaired
regulatory feedback.
In the striatum, DAT is localised to the plasma membranes of
axon varicosities and terminals that contain synaptic vesicles, thus
supporting its role in regulating and terminating extracellular
dopamine activity occurring via synaptic vesicular release.31 DAT
is also localised to non-synaptic region which may play a role in
regulation of extracellular dopamine associated with volume trans-
mission in which dopamine may diffuse to act functionally across
long ranges.32 DAT localisation in a non-synaptic region may also
play a role in regulating dopamine activity associated with reverse
transport of dopamine through the plasma membrane, a mechan-
ism implicated in the actions of amphetamine.33 34 β-CIT is likely
measuring plasmalemmal rather than intracellular DAT. In pri-
mates, β-CIT is dramatically reduced following amphetamine.
Since amphetamine is a substrate of DAT, the observed reduced
binding is likely reﬂecting DAT internalisation suggesting that
β-CIT does not bind signiﬁcantly to internalised DATor that inter-
nalised DAT has lower binding afﬁnity to β-CIT.35
This study is limited by the small sample size and mixed
ICDs. Larger studies speciﬁcally focusing on punding behaviours
may be indicated to differentiate underlying mechanisms from
ICDs. As the study is cross sectional, we cannot determine
whether the decreased DAT is secondary to the dopaminergic
medication or is a predisposing risk factor. Further research
focusing on subtype differences or longitudinal studies is indi-
cated. Assessing the relative contribution of sensitivity of the D2
autoreceptor and DAT levels to the enhanced release of dopa-
mine would also be indicated.
We show that PD+ICD subjects have lower DAT binding
compared to PD−ICD subjects. An effect on DAT regulation is
consistent with observations in substance use disorders.
Decreased reuptake may account for some of the enhancement
in dopamine activity beyond that of dopamine release and may
also contribute to the behavioural effects.
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